Delving into the Latest Updates on Wayshine Biopharm with Synapse

Overview

Tags

Neoplasms

Nervous System Diseases

Respiratory Diseases

Small molecule drug

Biological products

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Nervous System Diseases	4
Neoplasms	4

Top 5 Drug Type	Count

Small molecule drug	3
Biological products	1

Top 5 Target	Count

ATM(Serine-protein kinase ATM)	1
VEGFR2(Vascular endothelial growth factor receptor 2)	1
EGFR x EGFRvIII	1

主要目的：PartA：评价 WSD0922-FU 治疗非小细胞肺癌患者中的安全性和耐受性；PartB: 评价 WSD0922-FU 治疗晚期非小细胞肺癌患者的有效性次要目的：PartA：评价 WSD0922-FU 在非小细胞肺癌患者中的药代动力学特征；评价 WSD0922-FU 对非小细胞肺癌患者的初步有效性；PartB:评价 WSD0922-FU 治疗晚期非小细胞肺癌患者中的安全性和初步有效性

[Translation]

Primary objectives: Part A: Evaluate the safety and tolerability of WSD0922-FU in patients with non-small cell lung cancer; Part B: Evaluate the effectiveness of WSD0922-FU in patients with advanced non-small cell lung cancer Secondary objectives: Part A: Evaluate the pharmacokinetic characteristics of WSD0922-FU in patients with non-small cell lung cancer; Evaluate the preliminary effectiveness of WSD0922-FU in patients with non-small cell lung cancer; Part B: Evaluate the safety and preliminary effectiveness of WSD0922-FU in patients with advanced non-small cell lung cancer

Start Date-

Sponsor / Collaborator

Pharmaron Beijing Co., Ltd.

[+1]

NCT06631989 / RecruitingPhase 1/2

A Phase I/II Multicenter, Open Label, Single-arm Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of WSD0922-FU in the Treatment of Advanced Non-small Cell Lung Cancer

This study is a multicenter, open label, single-arm phase I/II clinical study of WSD0922-FU conducted in China, including Part A (dose escalation and expansion study) and Part B (dose extension). To explore the safety, tolerability, pharmacokinetic characteristics and efficacy of WSD0922-FU in patients with non-small cell lung cancer (NSCLC) with C797S mutation after first-line third-generation EGFR-TKI resistance (Osimertinib, Almonertinib, Furmonertinib, Befotertinib).

Start Date21 Aug 2024

Sponsor / Collaborator

Wayshine Biopharm

100 Clinical Results associated with Wayshine Biopharm

Login to view more data

0 Patents (Medical) associated with Wayshine Biopharm

Login to view more data

100 Deals associated with Wayshine Biopharm

Login to view more data

100 Translational Medicine associated with Wayshine Biopharm

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 23 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

1

Preclinical

IND Approval

1

Phase 2 Clinical

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

WSD-0922 ( EGFR x EGFRvIII )	Advanced Lung Non-Small Cell Carcinoma More	Phase 2 Clinical
WSD-0628 ( ATM )	Glioma More	IND Approval
WSD-1227 ( VEGFR2 )	Brain metastases More	Preclinical
WSD0329	Brain metastases More	Discovery